Experimental study of vitreoretinal proliferation inhibition by the use of hypericin;Estudo experimental da inibição da proliferação vitreorretiniana pelo uso da hiperecina

Arquivos Brasileiros de Oftalmologia

Volumn 72, Issue 5, 2009, Pages 650-654

  Machado, Roberto Augusto Fernandes ^a   Casella, Antonio Marcelo Barbante ^a   Malaguido, Marcus Rudolph ^a   Oguido, Ana Paula Miyagusko Taba ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Antidepressive agents therapeutic use; Disease models, animal; Eye injuries; Rabbits; Retinal detachment; Vitreoretinopathy, proliferative etiology; Vitreoretinopathy, Proliferative prevention control; Wound healing

Indexed keywords

EID: 74049114497     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/s0004-27492009000500010     Document Type: Article

References (28)

1. Ryan SJ. Traction retinal detachment. XLIX Edward Jackson Memorial Lecture. Am J Ophthalmol. 1993;115(1):1-20. Review.
2. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43(1):3-18.
3. Girard P, Mimoun G, Karpouzas I, Montefiore G. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina. 1994; 14(5):417-24.
4. Aaberg TM. Management of anterior and posterior proliferative vitreoretinopathy. XLV. Edward Jackson memorial lecture. Am J Ophthalmol. 1988;106(5): 519-32. Review.
5. Lewis H, Aaberg TM, Abrams GW, McDonalds HR, Williams GA, Mieler WF. Subretinal membranes in proliferative vitreoretinopathy. Ophthalmology. 1989;96(9):1403-14; discussion 1414-5.
6. Federman JL, Eagle RC Jr. Extensive peripheral retinectomy combined with posterior 360 degrees retinotomy for retinal reattachment in advanced proliferative vitreoretinopathy cases. Ophthalmology. 1990;97(10):1305-20.
7. Lewis H, Aaberg TM, Abrams GW. Causes of failure of the initial vitreoretinal surgery for severe proliferative vitreoretinopathy. Am J Ophthalmol. 1991; 111(1):8-14.
8. Lewis H, Aaberg TM. Causes of failure after repeat vitreoretinal surgery for recurrent proliferative vitreoretinopathy. Am J Ophthalmol. 1991;111(1):15-9.
9. Glaser BM, Carter JB, Kuppermann BD, Michels RG. Perfluoro-octane in the treatment of giant tears with proliferative vitreoretinopathy. Ophthalmology. 1991;98(11):1613-21.
10. Coll GE, Chang S, Sun J, Wieland MR, Berrocal MH. Perfluorcarbon liquid in the management of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1995;102(4):630-8; discussion 638-9.
11. Stern WH, Lewis GP, Erickson PA, Guerin CJ, Anderson DH, Fisher SK, O'Donnell JJ. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Am J Ophthalmol. 1983;96(1):33-42.
12. Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol. 1998;126(4):550-9.
13. Kon CH, Occleston NL, Foss A, Sheridan C, Aylward GW, Khaw PT. Effects of single, short-term exposures of human retinal pigment epithelial cells to thiotepa or 5-fluorouracil: implications for the treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 1998;82(5):554-60.
14. Yang CS, Khawly JA, Hainsworth DP, Chen SN, Ashton P, Guo H, Jafe GJ. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol. 1998;116(1):69-77.
15. Ozerdem U, Mach-Hofacre B, Keefe K, Pham T, Soules K, Appelt K, Freeman WR. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy. Ophthalmic Res. 2001;33(1):20-3.
16. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, Aylward GW. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001; 108(7):1179-83. Comment in: Ophthalmology. 2001;108(7):1177-8. Ophthalmology. 2002;109(5):829-30; author reply 830.
17. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol. 1980;89(1):131-6.
18. Hui YN, Hu D. Prevention of experimental proliferative vitreoretinopathy with daunomycin and triamcinolone based on the time course of the disease. Graefes Arch Clin Exp Ophthalmol. 1999;237(7):601-5.
19. Yoshida A, Elner SG, Bian ZM, Elner VM. Induction of interleukin-8 in human retinal pigment epithelial cells after denuding injury. Br J Ophthalmol. 2001; 85(7):872-6.
20. Blumenkranz MS, Ophir A, Claflin AJ, Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol. 1982;94(4):458-67.
21. Hida T, Chandler DB, Sheta SM. Classification of the stages of proliferative vitreoretinopathy in a refined experimental model in the rabbit eye. Graefes Arch Clin Exp Ophthalmol. 1987;225(4):303-7.
22. Tahara YR, Sakamoto TR, Oshima YR, Ishibashi TR, Inomata HR, Murata TR, et al. The antidepressant hypericin inhibits progression of experimental proliferative vitreoretinopathy. Curr Eye Res. 1999;19(4):323-9.
23. Gao Q, Hui Y, Wang Y. [Effects of hypericin on traumatic proliferative vitreoretinopathy in rabbits]. Yan Ke Xue Bao. 2002;18(4):240-5. Chinese.
24. Alonso JR. Tratado de fitomedicina: bases clinicas y farmacológicas. Buenos Aires: Isis Ediciones S.R.L.; 1998.
25. Agostinis P, Donella-Deana A, Cuveele J, Vandenbogaerde A, Sarno S, Merlevede W, de Witte P. A comparative analysis of photosensitized inhibition of growth-factor regulated protein kinases by hypericin-derivatives. Biochem Biophys Res Commun. 1996;220(3):613-7.
26. Frenzel EM, Neely KA, Walsh AW, Cameron JD, Gregerson DS. A new model of proliferative vitreoretinopathy. Invest Ophthal Vis Sci. 1998;39(11):2157-64.
27. Higuchi A, Yamada H, Yamada E, Jo N, Matsumura M. Hypericin inhibits pathological retinal neovascularization in a mouse model of oxygen-induced retinopathy. Mol Vis. 2008;14:249-54.
28. Sheu SJ, Sakamoto T, Osusky R, Wang HM, Ogden TE, Ryan SJ, et al. Transforming growth factor-beta regulates human retinal pigment epithelial cell phagocytosis by influencing a protein kinase C-dependent pathway. Graefes Arch Clin Exp Ophthalmol. 1994;232(11):695-701.